The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 1, 2011, Pages 184-197

  Tomasetti, Carmine ^a   Dell'Aversano, Carmela ^a   Iasevoli, Felice ^a   Marmo, Federica ^a   de Bartolomeis, Andrea ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bipolar disorder; Dopamine; Homer1a; Quetiapine; Valproate

Indexed keywords

CITALOPRAM; GLYCOGEN SYNTHASE KINASE 3BETA; HALOPERIDOL; MITOGEN ACTIVATED PROTEIN KINASE; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN HOMER 1A; PROTEIN HOMER 1B; PROTEIN HOMER 1C; QUETIAPINE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR CINGULATE; ARTICLE; BRAIN CORTEX; CAUDATE NUCLEUS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG MEGADOSE; GENE EXPRESSION REGULATION; GENE INDUCTION; LOW DRUG DOSE; MALE; MONOTHERAPY; MOTOR CORTEX; NONHUMAN; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; POSTSYNAPTIC DENSITY; PREMOTOR CORTEX; PUTAMEN; RAT; UPREGULATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; CARRIER PROTEINS; CEREBRAL CORTEX; CORPUS STRIATUM; DRUG COMBINATIONS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TIME FACTORS;

EID: 78650955419     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.10.025     Document Type: Article

References (106)

1. Alimohamad H., Rajakumar N., Seah Y.H., Rushlow W. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 2005, 57:533-542.
2. Amargos-Bosch M., Adell A., Artigas F. Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex. J Neurochem 2007, 102:550-561.
3. Ambesi-Impiombato A., D'Urso G., Muscettola G., de Bartolomeis A. Method for quantitative in situ hybridization histochemistry and image analysis applied for Homer1a gene expression in rat brain. Brain Res Brain Res Protoc 2003, 11:189-196.
4. Ambesi-Impiombato A., Panariello F., Dell'aversano C., Tomasetti C., Muscettola G., de Bartolomeis A. Differential expression of Homer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain. Synapse 2007, 61:429-439.
5. Ango F., Prezeau L., Muller T., Tu J.C., Xiao B., Worley P.F., et al. Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature 2001, 411:962-965.
6. Aubry J.M., Schwald M., Ballmann E., Karege F. Early effects of mood stabilizers on the .Akt/GSK-3beta signaling pathway and on cell survival and proliferation. Psychopharmacology (Berl) 2009, 205:419-429.
7. Beaulieu J.M., Gainetdinov R.R., Caron M.G. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 2009, 49:327-347.
8. Benedetti F., Serretti A., Colombo C., Lorenzi C., Tubazio V., Smeraldi E. A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 2004, 368:123-126.
9. Benedetti F., Serretti A., Pontiggia A., Bernasconi A., Lorenzi C., Colombo C., et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50T/C SNP. Neurosci Lett 2005, 376:51-55.
10. Brakeman P.R., Lanahan A.A., O'Brien R., Roche K., Barnes C.A., Huganir R.L., et al. Homer: a protein that selectively binds metabotropic glutamate receptors. Nature 1997, 386:284-288.
11. Browning J.L., Patel T., Brandt P.C., Young K.A., Holcomb L.A., Hicks P.B. Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biol Psychiatry 2005, 57:617-623.
12. Calabrese J.R., Elhaj O., Gajwani P., Gao K. Clinical highlights in bipolar depression: focus on atypical antipsychotics. J Clin Psychiatry 2005, 66(Suppl 5):26-33.
13. Chen B., Wang J.F., Hill B.C., Young L.T. Lithium and valproate differentially regulate brain regional expression of phosphorylated CREB and c-Fos. Brain Res Mol Brain Res 1999, 70:45-53.
14. Chen G., Henter I.D., Manji H.K. Translational research in bipolar disorder: emerging insights from genetically based models. Mol Psychiatry 2010, 15:883-895.
15. Cochran S.M., McKerchar C.E., Morris B.J., Pratt J.A. Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol. Neuropharmacology 2002, 43:394-407.
16. de Bartolomeis A., Iasevoli F. The Homer family and the signal transduction system at glutamatergic postsynaptic density: potential role in behavior and pharmacotherapy. Psychopharmacol Bull 2003, 37:51-83.
17. de Bartolomeis A., Aloj L., Ambesi-Impiombato A., Bravi D., Caraco C., Muscettola G., et al. Acute administration of antipsychotics modulates Homer striatal gene expression differentially. Brain Res Mol Brain Res 2002, 98:124-129.
18. Dell'aversano C., Tomasetti C., Iasevoli F., de Bartolomeis A. Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders. Brain Res Bull 2009, 79:123-129.
19. Denys D., Klompmakers A.A., Westenberg H.G. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl) 2004, 176:195-203.
20. Deutch A.Y., Duman R.S. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience 1996, 70:377-389.
21. Dong E., Nelson M., Grayson D.R., Costa E., Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci USA 2008, 105:13614-13619.
22. Dragunow M., Williams M., Faull R.L. Haloperidol induces Fos and related molecules in intrastriatal grafts derived from fetal striatal primordia. Brain Res 1990, 530:309-311.
23. Einat H., Yuan P., Gould T.D., Li J., Du J., Zhang L., et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 2003, 23:7311-7316.
24. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004, 36:131-137.
25. Flores-Hernandez J., Cepeda C., Hernandez-Echeagaray E., Calvert C.R., Jokel E.S., Fienberg A.A., et al. Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J Neurophysiol 2002, 88:3010-3020.
26. Fountoulakis K.N., Vieta E., Sanchez-Moreno J., Kaprinis S.G., Goikolea J.M., Kaprinis G.S. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord 2005, 86:1-10.
27. Fumagalli F., Molteni R., Calabrese F., Frasca A., Racagni G., Riva M.A. Chronic fluoxetine administration inhibits extracellular signal-regulated kinase 1/2 phosphorylation in rat brain. J Neurochem 2005, 93:1551-1560.
28. Gallo A., Lapointe S., Stip E., Potvin S., Rompre P.P. Quetiapine blocks cocaine-induced enhancement of brain stimulation reward. Behav Brain Res 2010, 208:163-168.
29. Ghasemzadeh M.B., Vasudevan P., Mueller C., Seubert C., Mantsch J.R. Neuroadaptations in the cellular and postsynaptic group 1 metabotropic glutamate receptor mGluR5 and Homer proteins following extinction of cocaine self-administration. Neurosci Lett 2009, 452:167-171.
30. Ghasemzadeh M.B., Vasudevan P., Mueller C., Seubert C., Mantsch J.R. Region specific alterations in glutamate receptor expression and subcellular distribution following extinction of cocaine self-administration. Brain Res 2009, 1267:89-102.
31. Gijsman H.J., Geddes J.R., Rendell J.M., Nolen W.A., Goodwin G.M. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004, 161:1537-1547.
32. Giuffrida R., Musumeci S., D'Antoni S., Bonaccorso C.M., Giuffrida-Stella A.M., Oostra B.A., et al. A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome. J Neurosci 2005, 25:8908-8916.
33. Gobbi G., Janiri L. Sodium- and magnesium-valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex. Psychopharmacology (Berl) 2006, 185:255-262.
34. Gould T.D., Manji H.K. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005, 30:1223-1237.
35. Green M.J., Cahill C.M., Malhi G.S. The cognitive and neurophysiological basis of emotion dysregulation in bipolar disorder. J Affect Disord 2007, 103:29-42.
36. Grimes C.A., Jope R.S. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 2001, 78:1219-1232.
37. Guidotti A., Dong E., Kundakovic M., Satta R., Grayson D.R., Costa E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol Sci 2009, 30:55-60.
38. Hao Y., Creson T., Zhang L., Li P., Du F., Yuan P., et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 2004, 24:6590-6599.
39. Hesslinger B., Normann C., Langosch J.M., Klose P., Berger M., Walden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 1999, 19:310-315.
40. Huang M., Ichiwaka J., Li Z., Dai J., Meltzer H.Y. Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology (Berl) 2006, 185:274-281.
41. Huang M., Li Z., Ichikawa J., Dai J., Meltzer H.Y. Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex. Brain Res 2006, 1099:44-55.
42. Iasevoli F., Tomasetti C., Ambesi-Impiombato A., Muscettola G., de Bartolomeis A. Dopamine receptor subtypes contribution to Homer1a induction: Insights into antipsychotic molecular action. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:813-821.
43. Iasevoli F., Fiore G., Cicale M., Muscettola G., de Bartolomeis A. Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions. Psychiatry Res 2010, 117:255-260.
44. Ichikawa J., Meltzer H.Y. Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation. Eur J Pharmacol 1999, 380:R1-R3.
45. Invernizzi R., Velasco C., Bramante M., Longo A., Samanin R. Effect of 5-HT1A receptor antagonists on citalopram-induced increase in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus. Neuropharmacology 1997, 36:467-473.
46. Izumi T., Inoue T., Kitaichi Y., Nakagawa S., Koyama T. Target brain sites of the anxiolytic effect of citalopram, a selective serotonin reuptake inhibitor. Eur J Pharmacol 2006, 534:129-132.
47. Jiao H., Zhang L., Gao F., Lou D., Zhang J., Xu M. Dopamine D(1) and D(3) receptors oppositely regulate NMDA- and cocaine-induced MAPK signaling via NMDA receptor phosphorylation. J Neurochem 2007, 103:840-848.
48. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004, 29:95-102.
49. Kammermeier P.J. Endogenous homer proteins regulate metabotropic glutamate receptor signaling in neurons. J Neurosci 2008, 28:8560-8567.
50. Kang U.G., Seo M.S., Roh M.S., Kim Y., Yoon S.C., Kim Y.S. The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett 2004, 560:115-119.
51. Kapur S., Wadenberg M.L., Remington G. Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Can J Psychiatry 2000, 45:241-246.
52. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003, 305:625-631.
53. Kato T. Molecular neurobiology of bipolar disorder: a disease of 'mood-stabilizing neurons'?. Trends Neurosci 2008, 31:495-503.
54. Kato A., Fukazawa Y., Ozawa F., Inokuchi K., Sugiyama H. Activation of ERK cascade promotes accumulation of Vesl-1S/Homer-1a immunoreactivity at synapses. Brain Res Mol Brain Res 2003, 118:33-44.
55. Lewis D.A., Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000, 28:325-334.
56. Li X., Zhu W., Roh M.S., Friedman A.B., Rosborough K., Jope R.S. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004, 29:1426-1431.
57. Li Y.C., Xi D., Roman J., Huang Y.Q., Gao W.J. Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. J Neurosci 2009, 29:15551-15563.
58. Liegeois J.F., Ichikawa J., Meltzer H.Y. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 2002, 947:157-165.
59. Liu X.Y., Chu X.P., Mao L.M., Wang M., Lan H.X., Li M.H., et al. Modulation of D2R-NR2B interactions in response to cocaine. Neuron 2006, 52:897-909.
60. Lopez-Gil X., Artigas F., Adell A., Li M.H., et al. Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex. Curr Pharm Des 2010, 16:502-515.
61. Mazza M., Squillacioti M.R., Pecora R.D., Janiri L., Bria P. Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial. Expert Opin Pharmacother 2008, 9:3145-3149.
62. Merchant K.M., Dorsa D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc Natl Acad Sci USA 1993, 90:3447-3451.
63. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 1990, 54:1755-1760.
64. Montezinho L.P., Mork A., Duarte C.B., Penschuck S., Geraldes C.F., Castro M.M. Effects of mood stabilizers on the inhibition of adenylate cyclase via dopamine D(2)-like receptors. Bipolar Disord 2007, 9:290-297.
65. Natesan S., Reckless G.E., Barlow K.B., Nobrega J.N., Kapur S. Amisulpride the 'atypical' atypical antipsychotic-comparison to haloperidol, risperidone and clozapine. Schizophr Res 2008, 105:224-235.
66. Ninan I., Jardemark K.E., Wang R.Y. Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 2003, 48:66-79.
67. Orsetti M., Di Brisco F., Canonico P.L., Genazzani A.A., Ghi P. Gene regulation in the frontal cortex of rats exposed to the chronic mild stress paradigm, an animal model of human depression. Eur J Neurosci 2008, 27:2156-2164.
68. Orsetti M., Di Brisco F., Rinaldi M., Dallorto D., Ghi P. Some molecular effectors of antidepressant action of quetiapine revealed by DNA microarray in the frontal cortex of anhedonic rats. Pharmacogenet Genomics 2009, 19:600-612.
69. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1997, Academic Press Inc, Sydney, Australia.
70. Pira L., Mongeau R., Pani L. The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur J Pharmacol 2004, 504:61-64.
71. Plant N., Barber P., Horner E., Cockburn C.L., Gibson G., Bugelski P., et al. Differential gene expression in rats following subacute exposure to the anticonvulsant sodium valproate. Toxicol Appl Pharmacol 2002, 183:127-134.
72. Polese D., de Serpis A.A., Ambesi-Impiombato A., Muscettola G., de Bartolomeis A. Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine. Neuropsychopharmacology 2002, 27:906-913.
73. Pouyssegur J., Volmat V., Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol 2002, 64:755-763.
74. Pozzi L., Hakansson K., Usiello A., Borgkvist A., Lindskog M., Greengard P., et al. Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. J Neurochem 2003, 86:451-459.
75. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000, 68:29-39.
76. Richtand N.M., Welge J.A., Logue A.D., Keck P.E., Strakowski S.M., McNamara R.K. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 2007, 32:1715-1726.
77. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992, 46:315-328.
78. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994, 271:1058-1066.
79. Roh M.S., Eom T.Y., Zmijewska A.A., De Sarno P., Roth K.A., Jope R.S. Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine. Biol Psychiatry 2005, 57:278-286.
80. Sarantis K., Matsokis N., Angelatou F. Synergistic interactions of dopamine D1 and glutamate NMDA receptors in rat hippocampus and prefrontal cortex: involvement of ERK1/2 signaling. Neuroscience 2009, 163:1135-1145.
81. Seamans J.K., Durstewitz D., Christie B.R., Stevens C.F., Sejnowski T.J. Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci USA 2001, 98:301-306.
82. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002, 47:27-38.
83. Seeman P., Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998, 3:123-134.
84. Shiraishi Y., Mizutani A., Mikoshiba K., Furuichi T. Coincidence in dendritic clustering and synaptic targeting of homer proteins and NMDA receptor complex proteins NR2B and PSD95 during development of cultured hippocampal neurons. Mol Cell Neurosci 2003, 22:188-201.
85. Shiraishi-Yamaguchi Y., Furuichi T. The Homer family proteins. Genome Biol 2007, 8:206.
86. Steiner H., Gerfen C.R. Cocaine-induced c-fos messenger RNA is inversely related to dynorphin expression in striatum. J Neurosci 1993, 13:5066-5081.
87. Sweatt J.D. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 2001, 76:1-10.
88. Szumlinski K.K., Lominac K.D., Kleschen M.J., Oleson E.B., Dehoff M.H., Schwarz M.K., et al. Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia. Genes Brain Behav 2005, 4:273-288.
89. Szumlinski K.K., Kalivas P.W., Worley P.F. Homer proteins: implications for neuropsychiatric disorders. Curr Opin Neurobiol 2006, 16:251-257.
90. Tappe A., Kuner R. Regulation of motor performance and striatal function by synaptic scaffolding proteins of the Homer1 family. Proc Natl Acad Sci USA 2006, 103:774-779.
91. Tomasetti C., Dell'Aversano C., Iasevoli F., de Bartolomeis A. Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action. Neuroscience 2007, 150:144-158.
92. Tu J.C., Xiao B., Yuan J.P., Lanahan A.A., Leoffert K., Li M., et al. Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron 1998, 21:717-726.
93. Tu J.C., Xiao B., Naisbitt S., Yuan J.P., Petralia R.S., Brakeman P., et al. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 1999, 23:583-592.
94. Wadenberg M.L., Soliman A., VanderSpek S.C., Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001, 25:633-641.
95. Wang J.Q., Tang Q., Parelkar N.K., Liu Z., Samdani S., Choe E.S., et al. Glutamate signaling to Ras-MAPK in striatal neurons: mechanisms for inducible gene expression and plasticity. Mol Neurobiol 2004, 29:1-14.
96. Weis S., Llenos I.C., Dulay J.R., Verma N., Sabunciyan S., Yolken R.H. Changes in region- and cell type-specific expression patterns of neutral amino acid transporter 1 (ASCT-1) in the anterior cingulate cortex and hippocampus in schizophrenia, bipolar disorder and major depression. J Neural Transm 2007, 114:261-271.
97. Weisler R., Joyce M., McGill L., Lazarus A., Szamosi J., Eriksson H. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009, 14:299-313.
98. Willuhn I., Sun W., Steiner H. Topography of cocaine-induced gene regulation in the rat striatum: relationship to cortical inputs and role of behavioural context. Eur J Neurosci 2003, 17:1053-1066.
99. Wood M.D., Scott C., Clarke K., Cato K.J., Patel N., Heath J., et al. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets 2006, 5:445-452.
100. Xiao B., Tu J.C., Petralia R.S., Yuan J.P., Doan A., Breder C.D., et al. Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of homer-related, synaptic proteins. Neuron 1998, 21:707-716.
101. Yamamura S., Ohoyama K., Hamaguchi T., Kashimoto K., Nakagawa M., Kanehara S., et al. Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex. Psychopharmacology (Berl) 2009, 206:243-258.
102. Yanahashi S., Hashimoto K., Hattori K., Yuasa S., Iyo M. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol. Brain Res 2004, 1011:84-93.
103. Yang L., Mao L., Tang Q., Samdani S., Liu Z., Wang J.Q. A novel Ca2+-independent signaling pathway to extracellular signal-regulated protein kinase by coactivation of NMDA receptors and metabotropic glutamate receptor 5 in neurons. J Neurosci 2004, 24:10846-10857.
104. Yatham L.N., Goldstein J.M., Vieta E., Bowden C.L., Grunze H., Post R.M., et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005, 66(Suppl 5):40-48.
105. Yuan P., Zhou R., Wang Y., Li X., Li J., Chen G., et al. Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. J Affect Disord 2010, 124:164-169.
106. Zhang W., Perry K.W., Wong D.T., Potts B.D., Bao J., Tollefson G.D., et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000, 23:250-262.